H-Arg-Gln-OH hydrochloride salt structure
|
Common Name | H-Arg-Gln-OH hydrochloride salt | ||
---|---|---|---|---|
CAS Number | 2483-17-2 | Molecular Weight | 302.33 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C11H22N6O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of H-Arg-Gln-OH hydrochloride saltArginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy[1]. |
Name | (2S)-5-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid |
---|---|
Synonym | More Synonyms |
Description | Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy[1]. |
---|---|
Related Catalog | |
Target |
VEGF[1] |
In Vitro | Arginyl-Glutamine (0.5-1.5 mM; 48 h) 会导致人类 RPE 细胞中可溶性 VEGF 在培养基中的表达呈统计学意义上的剂量依赖性下降[1]。 |
In Vivo | Arginyl-Glutamine (1-5 g/kg/day as a hydrochloride salt; i.p.; twice daily) 显著抑制小鼠氧诱导视网膜病变 (OIR) 模型中的视网膜新生血管[1]。 Animal Model: C57BL6/J mouse pups, oxygen-induced retinopathy (OIR) model[1] Dosage: 1.0, 2.5, or 5 g/kg per day Administration: Intraperitoneal injection, twice daily Result: Significantly decreased preretinal nuclei. Reduced neovascular tufts and vascular leakage in retinal vessels. Reduced preretinal neovascularization by 82% ± 7% and reduced VEGF mRNA by 64% ± 9% at 5 g/kg per day. |
References |
Molecular Formula | C11H22N6O4 |
---|---|
Molecular Weight | 302.33 |
Exact Mass | 338.14700 |
PSA | 197.41000 |
LogP | 1.19630 |
L-Arginyl-L-glutamin-acetat |
Arginylglutamine |
Glutamine,N2-L-arginyl-(6CI,7CI) |
L-Arg-L-Gln |
L-Glutamine,N2-L-arginyl |
L-Glutamine,L-arginyl |
Glutamine,N2-L-arginyl-,L-(8CI) |
N2-L-Arginyl-L-glutamin |
N2-L-arginyl-L-glutamine |
L-Arginyl=>L-glutamin |
L-arginyl-L-glutamine |
H-ARG-GLN-OH |